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STATE OF THE ART: CONCISE REVIEW
Salvage Therapy in Patients with Advanced Non-small Cell
Lung Cancer
Pablo M. Bedano, MD, and Nasser H. Hanna, MD
Patients with advanced non-small cell lung cancer continue to have
a poor prognosis; most die from the disease within 1 year. Chemo-
therapy is beneficial for some patients in the first-line metastatic
setting. Three agents, namely docetaxel, pemetrexed, and erlotinib,
are approved by the United States Food and Drug Administration as
treatment in the second-line setting. In this article, we examine the
data supporting the use of these agents in the second-line setting and
review data from other completed trials. Lastly, we propose strate-
gies to advance the treatment of patients with non-small cell lung
cancer.
(J Thorac Oncol. 2006;1: 582–587)
Lung cancer represents a significant cause of morbidity andmortality in the United States and worldwide.1,2 Advances
in the treatment of patients with non-metastatic lung cancer
have been realized in the last few years, which will result in
fewer patients who will die from this disease. The greatest
reduction in the burden of lung cancer will be realized only
when decreased tobacco consumption becomes commonplace
throughout the world. Until such time, we will continue to
care for hundreds of thousands of patients with metastatic
NSCLC each year.
Modest gains in survival time and improvements in
overall quality of life (Qol) are associated with the use of
chemotherapy in the first-line metastatic setting, primarily for
patients with an ECOG performance status (PS) of 0 or 1.3–6
Routine use of 5HT3 antagonists and other improvements in
supportive care have allowed most patients to tolerate che-
motherapy, and most are treated for four to six cycles with
first-line therapy. Unfortunately, disease progression after
first-line therapy is universal in this patient population, usu-
ally within 3 to 5 months of first-line chemotherapy.3 Sur-
vival times remain poor, with most patients dying within 1
year. The effects of cancer on the individual are devastating:
weight loss, diminished appetite, profound fatigue, breath-
lessness, pain, and wasting are common. Ongoing efforts to
find improved therapies remain a great challenge. Recently
conducted randomized trials have demonstrated the benefits
of second- and even third-line therapy. In this article, we
examine the data supporting the use of these agents in the
second-line setting and review data from other completed
trials. We propose strategies to advance the treatment of
patients with NSCLC.
Docetaxel
Before 2000, evidence that use of second-line chemo-
therapy for patients with advanced NSCLC resulted in a
survival benefit over best supportive care (BSC) alone was
lacking, and no drugs were approved for use by the United
States Food and Drug Administration (FDA). In a landmark
study, Shepherd et al.7 reported that treatment with docetaxel
75 mg/m2 IV once every 3 weeks could improve survival
versus BSC among patients with recurrent NSCLC previ-
ously treated with chemotherapy. Initially, patients in the
docetaxel arm received 100 mg/m2; after several patients died
from drug-related adverse events, docetaxel was modified to
75 mg/m2. Overall, 49 patients were treated with 100 mg/m2,
55 patients received 75 mg/m2, and 100 patients were in the
BSC arm. Patients enrolled in this trial had not received a
taxane in first-line treatment; 75% had a performance status
(PS) of 0/1, and 75% were being treated in the second-line
setting, whereas others had received two prior regimens.
Although the response rate was modest (7.1%) in the do-
cetaxel arm, more than 50% of patients had confirmed non-
progressive disease as their best response (Table 1). The
median survival time (MST) and 1-year survival rates were
prolonged in the docetaxel arm compared with BSC alone,
which confirms that patients with stable disease may also
realize survival benefits. As patients are treated with pallia-
tive intent, it is especially important in the second-line setting
that treatment does not cause toxicity that outweighs the
modest survival gains. Indeed, treatment with docetaxel im-
proved the overall QoL in the treated group as a whole.8
Confirmation of the benefits of docetaxel in the second-
line setting were realized at approximately the same time
when a multi-institutional randomized trial by Fossella et al.
was reported. In this trial, patients previously treated with
chemotherapy were randomized to either docetaxel 75 mg/m2
or 100 mg/m2 once every 3 weeks versus a control arm
consisting of either vinorelbine or ifosfamide.9 In contrast to
the study by Shepherd et al., patients in this study were
allowed treatment with a prior taxane (42% of patients).
Treatment with the higher dose of docetaxel did not confer
additional benefits versus the 75 mg/m2 dose but simply
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resulted in more toxicity to the patients. The activity of
docetaxel was confirmed to be modest (10%) but was
numerically higher than the control arm (1%). One-year
survival was prolonged for the docetaxel 75 mg/m2 arm.
Interestingly, the use of paclitaxel in the first-line setting was
not predictive of response to docetaxel on this study.
The United States FDA granted full approval for do-
cetaxel 75 mg/m2 IV once every 3 weeks in the second-line
setting in 1999 based on these randomized studies. The
introduction of second-line treatment fulfilled an unmet need
in lung cancer treatment. As with many agents, the use of
FDA-approved drugs may prove to have more side effects
and less effectiveness when used in a general patient popu-
lation, compared with a study group. Many patients treated
off-study may not be eligible for treatment in clinical trials
because of co-morbidities, poor PS, or other reasons. As the
use of docetaxel became widespread in the United States, it
became apparent that treatment with the approved dose and
schedule was intolerable for many patients, particularly be-
cause of neutropenic complications. In the study populations
of Fosella et al. and Shepherd et al., 54% had grade 4
neutropenia, and 67% had grade 3 or 4 neutropenia, respec-
tively (Table 2). The label for docetaxel lists an approximate
6% rate of febrile neutropenia, although this figure has ranged
from 3% to 15% in clinical trials. Based on a perceived
improved safety profile, regimens of lower dose docetaxel
given on a weekly basis were explored in phase II trials.
Additional improvements in efficacy were also hoped to be
realized as lower dose taxanes are thought to exert an addi-
tional anti-angiogenic effect. Initial phase II trials of weekly
docetaxel seemed to support its widespread use.10–12
Three randomized phase III trials comparing the every
3 weeks and weekly regimens of docetaxel have failed to
confirm improvements in efficacy.13–15 Docetaxel was given
at doses of 33 to 36 mg/m2 weekly for 6 of 8 weeks or 3 of
4 weeks. Response rates for weekly docetaxel are approxi-
mately 6%, median survival times are 5 to 6 months, and
1-year survival rates are 20% to 30%. The every 3 weeks
schedule was associated with increased incidence of neutro-
penia, infection, and alopecia, and the weekly schedule with
higher rates of nail changes, diarrhea, mucositis, and anemia.
The studies by Schuette et al. and Gridelli et al. also explored
Qol issues and failed to demonstrate significant differences.
When clinicians are faced with the decision on treatment in
the second-line setting, convenience to patients is of para-
mount importance, because survival gains are modest and life
expectancy is short. The randomized data fail to justify the
use of the more inconvenient weekly regimen of docetaxel for
most patients. A weekly regimen should be considered if
neutropenia is a primary concern.
Pemetrexed
Pemetrexed has demonstrated single-agent activity in
NSCLC, with a RR of 17% to 23% in phase II studies of
previously untreated patients.16,17 A phase II study of pem-
etrexed in patients with advanced NSCLC who had disease
progression during or within 3 months of completing first-line
chemotherapy (chemorefractory) demonstrated a response
rate of 8.9% and a MST of approximately 6 months.18 Results
of a phase III randomized trial comparing pemetrexed with
docetaxel in the second-line setting have been reported.19 In
this study, 571 patients received either pemetrexed 500
mg/m2 IV on day 1 with vitamin B12, folic acid, and dexa-
methasone or docetaxel 75 mg/m2 IV with dexamethasone
every 21 days. Of these patients, 88% had a PS of 0 or 1, 35%
had an objective response to first-line therapy, 50% had
received first-line chemotherapy within 3 months of entering
TABLE 1. Efficacy with Docetaxel 75 mg/m2 every 3 weeks
in Phase III studies
Patients





Hanna et al.19 288 8.8% 46.4% 2.9 months 7.9 months 29.7%
Fossella et al.9 120 6.7% 36% 8.5 weeks 5.7 months 32%
Shepherd et al.7 55 7.1% 47.3% 10.6 weeks 7.5 months 37%
Camps et al.13 131 9.3% 34.1% 2.7 months 6.6 months 27%
Schuette et al.14 103 12.6% 37.9% 3.4 months 6.3 months 26.9%
Gridelli et al.15 110 2.7% NR NR 21 weeks 21%
RR, response rate; SD, stable disease; TTP, time to progression; OS, overall
survival; NR, not reported.
TABLE 2. Grade 3/4 toxicities of weekly and every 3 weeks docetaxel, pemetrexed, and erlotinib
Shepherd et al.7
Docetaxel 75 mg/m2 (3W)
Fossella et al.9







Neutropenia 67.3% 54% 3.2% 5.3% NR
Febrileneutropenia 1.8% 8% 0.8% 1.9% NR
Infection 5.5% 0 NR 0 2%
Anemia 5.5% 0 4.8% 4.2% NR
Thrombocytopenia 0 2% 0.8% 2% NR
Nausea 3.6% 3% 3.2% 2.6% 3%
Rash NR NR 1.6% 0.8% 9%
Diarrhea 1.8% 2% 3.2% 0.4% 6%
Pneumonitis 1.8% NR NR 0 1%
Neurosensory 1.8% 1% 3.2% 0 NR
NR, not reported; 3W, every 3 weeks; 1W, every week.
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this trial, and only 25% of patients had received a prior
taxane. The RR for each agent was approximately 9%, and an
additional 45% of patients had stable disease. All efficacy
parameters were comparable between both agents (table 1),
but there were significant differences in the toxicity profiles
(table 2). Significantly more patients in the docetaxel arm
experienced grade 3/4 neutropenia (40.2% versus 5.35%; p
0.001), neutropenic fever (12.7% versus 1.9%; p  0.001),
and infection with neutropenia (3.3% versus 0%; p  0.004).
More patients in the docetaxel arm required hospitalization
and the use of growth factor support. Grade 3/4 non-hema-
tologic toxicities were similar in the two arms except for a
higher rate of alopecia in the docetaxel arm and higher rates
of ALT elevation in the pemetrexed arm. When considering
all grades of toxicity, more patients in the docetaxel arm also
experienced higher rates of diarrhea and neurosensory toxic-
ity. Both agents result in very low rates of grade 3/4 nausea,
but a substantial number of patients do experience grade 1 or
2 nausea. Because grade 1/2 nausea is unpleasant for the
patients, one must consider the use of prophylactic 5HT3
antagonists for both agents.
Epidermal Growth Factor Receptor Tyrosine
Kinase Inhibitors
The epidermal growth factor receptor (EGFR) has
proven to be an important target in some patients with
NSCLC. Although the EGFR is overexpressed in most cases
of NSCLC, inhibition of this target results in responses in
only 10% to 20% of patients.20 Two orally active tyrosine
kinase inhibitors (TKIs), gefitinib and erlotinib, have been
approved by the United States FDA for the treatment of
relapsed NSCLC. Despite no phase III data, gefitinib was
licensed by the United States FDA as monotherapy filling an
unmet need at the time for third-line therapy in NSCLC.
Approval was based on two phase II studies (IDEAL-1 and 2)
randomizing patients to two different doses of gefitinib,
which demonstrated a RR of approximately 10% with im-
provements in symptoms in 40% of patients.21,22 Response to
gefitinib seemed independent of whether it was given as
second- or third-line treatment (as was done in IDEAL-1) or
beyond third-line treatment (as in IDEAL-2). Gefitinib
seemed more active in Japanese patients, women, never
smokers, and those with adenocarcinoma. Although acceler-
ated approval was granted for gefitinib, confirmatory studies
were still required by the FDA to meet the requirements of
full licensing approval.
The Iressa Survival Evaluation in Lung Cancer (ISEL)
was a randomized, double-blind, placebo-controlled phase III
trial conducted in 28 countries. In this study, 1692 patients
with advanced NSCLC who had received at least one previ-
ous chemotherapy regimen were randomized in a 2 to 1 ratio
to gefitinib 250 mg once daily or placebo.23 The overall
response rate was significantly higher in the gefitinib group
(8% versus 1.3%; p  0.0001). In the exploratory subgroup
analysis, the largest difference in response was seen among
never smokers, women, patients with adenocarcinoma, and
patients of Asian origin, as expected from the results of the
two phase II trials. The most common adverse events were
similar to those observed in IDEAL-1 and IDEAL-2, predom-
inantly diarrhea and rash, mostly grade 1/2. The incidence of
pneumonitis was equal in both arms (1%). Disappointingly,
there was no statistically significant difference in median
survival between the two groups (Table 3). Based on this
study, gefitinib has been now pulled from the United States
market, except for patients who continue to have a response
to the drug.
Erlotinib is also a potent, reversible, orally active
EGFR-TKI. Shepherd et al. randomized 731 patients with
stage IIIB or IV NSCLC, with PS 0-3, who had received one
or two prior chemotherapy regimens in a 2 to1 ratio to
erlotinib 150 mg daily or placebo.24 The response rate was
8.9% for erlotinib and less than 1% in the placebo arm (p 
0.001). In contrast to chemotherapy, response to erlotinib was
independent of PS, number of prior regimens, or response to
prior therapy. An additional 35% of patients in the erlotinib
arm had stable disease, compared with 27% of patients in the
placebo arm; the median duration of response was 7.9 months
versus 3.7 months, and the PFS was 2.2 months versus 1.8
months (p  0.001). Based on this modest RR of 8.9% and
overall disease control rate of approximately 45%, effecting
the median survival seems unlikely, because usually more
than 50% of patients must benefit more from an intervention
to affect the median. However, the median was 6.7 months in
the erlotinib arm versus 4.7 months in the placebo arm (p 
0.001). Perhaps some patients who had progression as their
best response were also benefited in some way. Toxicities
were similar to all the previous trials using EGFR-TKIs, with
predominance of rash and diarrhea, with 5% of patients
discontinuing therapy. The incidence of pneumonitis was
equal in both groups. Erlotinib had a beneficial effect on
survival in almost all subgroups tested, although never-
smoking status was the factor most predictive of survival
gains. Tumor biopsy samples from the study participants
were used to determine whether responsiveness to erlotinib
was influenced by the status of EGFR expression, the number
of EGFR copies, or the presence of EGFR mutations.25 The
authors concluded that expression of EGFR and an increased
number of copies of EGFR were predictive of survival,
whereas EGFR mutational analysis was not. Despite these
findings, the timing of erlotinib in the salvage setting remains
undefined. The interactions between clinical and molecular
TABLE 3. Efficacy of gefitinib and erlotinib in phase III
studies of NSCLC





RR 8% 1% 8.9% 1%
SD 32% 31% 35% 27%
TTP 3 months 2.6 months 2.2 months 1.8 months
MST 5.6 months 5.1 months 6.7 months 4.7 months
1-year survival 27% 21% 31.2% 21.5%
RR, response rate; SD, stable disease; TTP, time to progression; MST, median
survival time.
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factors in determining the optimal sequence in which it can be
used with chemotherapy are still under investigation.
Why was erlotinib superior to placebo in a randomized
phase III study but gefitinib was not? One could speculate
that the dose of 150 mg of erlotinib is sufficient to effect
greater numbers of patients compared with 250 mg of ge-
fitinib. Indeed, 150 mg of erlotinib is equivalent to approxi-
mately 700 mg of gefitinib. Perhaps the higher dose of
erlotinib allowed for inhibition of some tumors with wild type
EGFR, whereas the lower dose of gefitinib was sufficient to
inhibit only mutated EGFR. Perhaps the disparate results
were the result of patient selection or chance alone. The
confidence intervals for survival do overlap. Interestingly, the
placebo arm of the erlotinib study performed worse than the
placebo arm of the gefitinib study (Table 3). Another plausi-
ble explanation is that erlotinib is a slightly more effective
drug than gefitinib. One must be careful, however, when
declaring one trial to be “positive” and another trial “nega-
tive.” In fact, the data with each agent seem nearly super-
imposable. Response rates, SD rates, and PFS seem very
similar. One-year survival was approximately 30% for each
agent, and the magnitude of change on the survival curves for
each study is also quite similar. Both agents seem to benefit
the same subgroups and are associated with a similar toxicity
profile. Most patients who benefited with erlotinib might
benefit similarly with gefitinib. Significant differences in the
magnitude of toxicity are evident, however, as skin and
gastrointestinal toxicities are dose-related.
Other Agents Tested in Phase III Studies
Topotecan is a water-soluble semisynthetic analogue of
the alkaloid camptothecin with activity against a wide range
of tumors. It has a specific mechanism of action via inhibition
of topoisomerase-1, resulting in damage during DNA repli-
cation and ultimately in tumor cell death.26 In the largest
second-line trial to date, Ramlau et al. randomized 829
patients with NSCLC with PD after one line of chemotherapy
to oral topotecan 2.3 mg/m2/d on days 1 to 5 every 3 weeks
versus docetaxel 75 mg/m2 IV once every 3 weeks.27 The
primary end point was survival with a non-inferiority design.
Most patients were PS 0/1 (86% and 84%), and more than
half of patients on each arm had progressed within 3 months
of completing first-line therapy. Response rates were equal
for both groups (5%), as was median survival (27.9 versus
30.7 weeks; log-rank p  0.057) and time to progression
(11.3 versus 13.1 weeks; log-rank p  0.0196), in both cases
numerically favoring the docetaxel arm. Despite this trend
toward benefits with docetaxel, the study did meet its non-
inferiority end point for topotecan. The rates of neutropenia
were similar, but the incidence of anemia and thrombocyto-
penia were much higher for topotecan. Nausea, vomiting, and
diarrhea were more common with topotecan, and neuropathy
and alopecia were more common with docetaxel. The impli-
cations of these results on regulatory approval for topotecan
are uncertain.
Combination Chemotherapy
Although several studies have demonstrated that the
combination of agents is more effective than single-agent
therapy in the first-line treatment of NSCLC, no randomized
phase III trials have been reported in the second-line setting.
Several single-arm trials and randomized phase II studies of
combination chemotherapy have been undertaken. Takeda et
al. randomized patients to docetaxel 60 mg/m2 day 1 or
docetaxel 60 mg/m2 on day 8 with gemcitabine 800 mg/m2 on
days 1 and 8, both repeated every 3 weeks until progression.28
Sixty-five patients were enrolled, and the trial had to be
terminated early because of an unexpectedly high incidence
of interstitial lung disease and three treatment-related deaths
in the docetaxel-gemcitabine arm. The MST and 1-year
survival were similar in both groups. In a randomized phase
II study of 130 patients with relapsed NSCLC, docetaxel 30
mg/m2 plus irinotecan 60 mg/m2 (day 1 and 8) were com-
pared with docetaxel 75 mg/m2 day 1, both repeated every 3
weeks.29 There were no significant differences in response
rates (20% versus 14%), MST (6.5 versus 6.4 months), and
1-year survival (37% versus 34%). The rates of neutropenia
and anemia were similar in both arms, but the combination
arm had higher rates of diarrhea (12% versus 3%; p  0.05)
and thrombocytopenia (17% versus 6%; p  0.04). Another
study evaluated the combination of vinorelbine 25 mg/m2 IV
plus gemcitabine 800 mg/m2 IV (both given on days 1 and 8)
in 39 patients with NSCLC refractory or resistant to plati-
num- or taxane-based therapy.30 Only one patient had an
objective response (2.6%), MST was 7.3 months, and 1-year
survival was 35%. The main adverse event was febrile neu-
tropenia, with a 13% incidence. Overall, these studies suggest
that combination chemotherapy is not more effective than
single-agent therapy, but it is associated with more toxicity.
Until randomized trials demonstrate improved efficacy for
combination therapy, single-agent therapy should remain
standard.
Newer Strategies
Angiogenesis, the process of new blood vessel forma-
tion, plays an important role in both the growth and metas-
tasis of NSCLC, making it an attractive target. Antiangio-
genic drugs are currently being tested in clinical trials, both
alone or combined with chemotherapy, including several
trials in lung cancer. Confirmatory evidence of the benefits of
bevacizumab in NSCLC was provided in a phase III trial
(E4599) by Sandler et al.31 Patients in this study were
randomized to receive carboplatin plus paclitaxel with or
without bevacizumab. The bevacizumab arm showed im-
provement in response rates (27% versus 10%), time to
progression (6.4 versus 4.5 months), and survival (12.5 ver-
sus 10.2 months) in the first-line setting.
Several small-molecule TKIs targeting different path-
ways important in angiogenesis have been developed. BAY
43-9006 (sorafenib) is a potent inhibitor of Raf-1 and active
against VEGFR-2, VEGFR-3, and PDGFR-.32 This agent
has shown activity in multiple tumor types, including a
recently published phase III trial in advanced renal cell
carcinoma.33 The most common adverse events seen are skin
rash and hand and foot syndrome. The Eastern Cooperative
Oncology Group (ECOG) is currently enrolling patients in a
phase II clinical trial of sorafenib in refractory NSCLC.
SU11248 (sutent) is a selective inhibitor of several protein
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tyrosine kinases, including VEGF-R types 1 to 3, PDGFR-,
and PDGFR-, which has also shown activity in renal can-
cer,34 as well as in imatinib-resistant gastrointestinal stromal
tumor.35 Both of these agents have been recently approved by
the United States FDA, sutent for use in metastatic renal cell
carcinoma and gastrointestinal stromal tumor, and sorafenib
for use in metastatic renal cell carcinoma.
Cetuximab is a chimeric antibody of the immunoglob-
ulin G1 subclass that targets and blocks the human EGFR.36
Cetuximab blocks the binding of EGF and TGF- to EGFR
and inhibits ligand-induced activation of the receptor. Cetux-
imab also stimulates EGFR internalization, effectively re-
moving the receptor from the cell surface for interaction with
the ligand, which may contribute to the inhibitory effects of
this antibody.37 Multiple studies have combined cetuximab
with chemotherapy in the first- and second-line setting.38–41
These studies have shown enhanced responses and/or im-
proved survival compared with historical controls, with skin
rash being the most common toxicity reported. Lilenbaum et
al.42 have reported their experience with single-agent cetux-
imab in the second-line setting. In this phase II clinical trial,
66 patients with recurrent or metastatic IIIb/IV NSCLC
treated with at least one previous regimen were treated with
cetuximab 400 mg/m2 on day 1, followed by 250 mg/m2
weekly until disease progression or unacceptable toxicity.
Three patients had an objective response (3.3%), and MST
was 8.1 months. Given the interesting ability of cetuximab to
resensitize cells to drugs to which they have become resistant
(in head/neck cancer and colon cancer), similar strategies are
being tested in NSCLC, including a Hoosier Oncology Group
dose escalation study of pemetrexed plus cetuximab and an
ongoing Imclone-run trial of pemetrexed or docetaxel with or
without cetuximab.
There is strong preclinical evidence to support simul-
taneous blockade of VEGF and the EGFR pathways. The
EGFR also seems to regulate VEGF,43,44 and several studies
have demonstrated that blockade of the EGFR results in an
antiangiogenic effect.45,46 Furthermore, data suggest that an
increased production of VEGF represents one mechanism by
which tumor cells escape anti-EGFR monoclonal antibody
therapy.47 A phase I/II study examined erlotinib and bevaci-
zumab as second-line therapy in patients with non-squamous
cell stage IIIB/IV NSCLC.48 In the phase I portion, erlotinib
150 mg/day orally plus bevacizumab 15 mg/kg IV every 21
days was established as the phase II dose, although no
dose-limiting toxicities were observed. Of the 34 patients in
phase II, eight had a response (20%), and the overall survival
was an encouraging 12.6 months. A randomized trial com-
paring erlotinib with and without bevacizumab is being con-
ducted.
CONCLUSIONS
There are currently three United States FDA-approved
agents for the second-line treatment of NSCLC: docetaxel 75
mg/m2 every 3 weeks, pemetrexed 500 mg/m2 every 3 weeks,
and erlotinib 150 mg orally daily. Based on the current
available data, the efficacy is similar among agents in a
general patient population, but there are significant differ-
ences in their toxicity profiles. The hematologic toxicity is
greater for docetaxel versus pemetrexed and erlotinib. Non-
hematologic toxicity, mainly rash and diarrhea, is greater for
erlotinib. Erlotinib should be strongly considered as second-
line treatment in never smokers who have not benefited from
first-line chemotherapy. For smokers who have benefited
from first-line chemotherapy and are maintaining a PS of 0 or
1, a trial of pemetrexed is reasonable. Most of the survival
benefit for any agent is appreciated mainly in PS 0 and 1
patients, and a trial of each agent is warranted in patients
maintaining a good PS.
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